The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, ...

Hims & Hers has shown impressive revenue growth, accelerating from 46% to 77%. Read why I downgrade HIMS stock from buy to ...

Hims & Hers hit the bullseye with its Super Bowl ad, sparking a surge in clicks to its site.The ad also hit a nerve with the ...

Drug industry calls out telehealth company Hims & Hers' Super Bowl ad touting its knock-off weight loss medications.

Hims has a great deal of meme potential, which could benefit the company by effectively acting as free advertising. Read more ...

Two U.S. senators wrote a letter to the Food and Drug Administration on Friday expressing concerns about an upcoming Super ...

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

Telehealth stock Hims & Hers ( HIMS) spiked more than 24% in trading Thursday, days after its Super Bowl ad promoting cheaper GLP-1 weight-loss drugs sparked controversy.

Hims & Hers stock price continues to fire on all cylinders this year and is hovering near its highest level on record. It has ...

During the Super Bowl, Hims & Hers Health aired a commercial called “Sick of the System.” But before the 60-second spot was ...